Negative Ionotropic Agents for the Treatment of Left Ventricular Outflow Tract Obstruction Due to Sigmoid Septum and Concentric Left Ventricular Hypertrophy

Heart Lung and Circulation

Volumn 20, Issue 9, 2011, Pages 579-586

  Ranasinghe, Isuru ^a   Yeoh, Thomas ^a   Yiannikas, John ^a  

^a ANZAC Research Institute   (Australia)

Author keywords

Blockers; Cardiac hypertrophy; Disopyramide; Localised septal hypertrophy

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; INOTROPIC AGENT; METOPROLOL;

ADULT; AGED; AORTA VALVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART SEPTUM DEFECT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; MITRAL VALVE; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIGMOID SEPTUM; ST SEGMENT DEPRESSION; THORAX PAIN; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; DISOPYRAMIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 79961126464     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2011.05.002     Document Type: Article

References (26)

1. Ommen S.R., Shah P.M., Tajik A.J. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart 2008, 94:1276-1281.
2. Maron M.S., Olivotto I., Betocchi S., Casey S.A., Lesser J.R., Losi M.A., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. NEJM 2003, 348(4):295-303.
3. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002, 287(March (10)):1308-1320.
4. Iida K., Sugishita Y., Ajisaka R., Matsumoto R., Higuchi Y., Tomizawa T., et al. Sigmoid septum causing left ventricular outflow tract obstruction: a case report. J Cardiogr - Suppl 1986, 16(1):237-247.
5. Ozaki K., Sakuma I., Mitsuma K., Suzuki T., Tsuchida K., Takahashi K., et al. Effect of cibenzoline and atenolol administration on dynamic left ventricular obstruction due to sigmoid-shaped septum. Circ J 2008, 72(12):2087-2091.
6. Wheeldon N.H., Pringle T.H., Lipworth B.J. Obstructive left ventricular hypertrophy, reversibility of outflow tract obstruction by drug therapy. Q J Med 1992, 84:629-636.
7. Kwon D.H., Setser R.M., Thamilarasan M., Popovic Z.V., Smedira N.G., Schoenhagen P., et al. Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Heart 2008, 94(October (10)):1295-1301.
8. Azzarelli S., Galassi A.R., Amico F., Giacoppo M., Argentino V., Fiscella A. Intraventricular obstruction in a patient with tako-tsubo cardiomyopathy. Int J Cardiol 2007, 121(October (2)):e22-e24.
9. Bolognesi R., Tsialtas D., Tiberti G., Conti M., Manca C. Left-ventricular outflow tract obstruction by mitral valve ring calcification and proximal septal hypertrophy in elderly patients. Gerontology 1996, 42:54-58.
10. Dinwoodey D., Skinner M., Maron M., Davidoff R., Ruberg F. Light-chain amyloidosis with echocardiographic features of hypertrophic cardiomyopathy. Am J Card 2007, 101(5):674-676.
11. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
12. Krasnow N. Subaortic septal bulge simulates hypertrophic cardiomyopathy by angulation of the septum with age, independent of focal hypertrophy, an echocardiographic study. J Am Soc Echocardigr 1997, (10):545-555.
13. Belenkie I., MacDonald R.P., Smith E.R. Localized septal hypertrophy: part of the spectrum of hypertrophic cardiomyopathy or an incidental echocardiographic finding?. Am Heart J 1988, 115:385.
14. Chen-Tournoux A., Fifer M.A., Picard M.H., Hung J. Use of tissue doppler to distinguish discrete upper ventricular septal hypertrophy from obstructive hypertrophic cardiomyopathy. Am J Cardiol 2008, 101:1498-1503.
15. Maron B.J., Gottdiener J.S., Epstein S.E. Significance of distribution of left ventricular bypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 1981, 48:418-428.
16. Spirito P., Maron B.J., Bonow R.O., Epstein S.E. Severe Functional limitation in patients with hypertrophic cardiomyopathy and only mild localized left ventricular hypertrophy. J Am Coll Cardiol 1986, 8:537-544.
17. Lever H.M., Karam R.F., Currie P.J., Healy B.P. Hypertrophic cardiomyopathy in the elderly, distinctions from the young based on cardiac shape. Circulation 1989, 79:580-589.
18. Henein M.Y., O'Sullivan C., Sutton G.C., Gibson D.G., Coats A.J. Stress-induced left ventricular outflow tract obstruction: a potential cause of dyspnea in the elderly. J Am Coll Cardiol 1997, 30(November (5)):1301-1307.
19. Doi Y.L., McKenna W.J., Oakley C.M., Goodwin J.F. 'Pseudo' systolic anterior motion in patients with hypertensive heart disease. Eur Heart J 1983, 4:838-845.
20. Nakagawa M., Sano N., Nobe S., Ichinose S., Yonemochi H., Saikawa T. Patients with mild hypertensive heart disease and left ventricular outflow tract obstruction: treatment with angiotensin II antagonists. Heart Vessels 2004, 19(September (5)):248-251.
21. Binder J., Ommen S.R., Gersh B.J., Van Driest S.L., Tajik A.J., Nishimura R.A., et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 2006, 81(April (4)):459-467.
22. Maron B.J., McKenna W.J., Danielson G.K., Kappenberger L.J., Kuhn H.J., Seidman C.E., et al. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines (Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy). Eur Heart J 2003, 10.1016/S0195-668X(03)00479-2.
23. Sherrid M.V., Barac I., McKenna W.J., Elliott P.M., Dickie S., Chojnowska L., et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005, 45(April (8)):1251-1258.
24. Udelson J.E., Bonow R.O., O'Gara P.T., Maron B.J., Van Lingen A., Bacharach S.L., et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989, 79(May (5)):1052-1060.
25. Bonow R.O., Dilsizian V., Rosing D.R., Maron B.J., Bacharach S.L., Green M.V. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 1985, 72(October (4)):853-864.
26. Epstein S.E., Rosing D.R. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981, 64(September (3):437-441.